Literature DB >> 16435187

Decreased plasma concentration of von Willebrand factor antigen (VWF:Ag) in patients with glycogen storage disease type Ia.

C Mühlhausen1, R Schneppenheim, U Budde, M Merkel, N Muschol, K Ullrich, R Santer.   

Abstract

Despite highly increased blood lipids, patients with glycogen storage disease type Ia (GSD Ia) do not develop premature vascular complications. Since this could be due to changes of coagulation factors, coagulation tests (including von Willebrand factor (VWF) antigen (VWF:Ag) ELISA, VWF:collagen binding activity (VWF:CB) and VWF multimer analysis) were performed in 10 GSD Ia patients, single cases of other GSD types, and in both healthy and hyperlipidaemic controls. In 60% of GSD Ia patients we found abnormal results, with a decrease of VWF:Ag and multimer analysis showing reduced intensity of individual oligomers in the presence of all multimers with a normal triplet structure. We interpret these findings as an acquired 'von Willebrand syndrome type I' in GSD Ia. The underlying metabolic mechanism and a potential role in the protection from vascular complication still needs to be evaluated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16435187     DOI: 10.1007/s10545-005-0184-9

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.750


  22 in total

1.  Luminography--an alternative assay for detection of von Willebrand factor multimers.

Authors:  R Schneppenheim; H Plendl; U Budde
Journal:  Thromb Haemost       Date:  1988-10-31       Impact factor: 5.249

2.  DDAVP infusion in five patients with type Ia glycogen storage disease and associated correction of prolonged bleeding times.

Authors:  G E Marti; M E Rick; J Sidbury; H R Gralnick
Journal:  Blood       Date:  1986-07       Impact factor: 22.113

3.  [Enzyme-linked immunoabsorbent assay of factor VIII-related antigen. Interest in study of Von Willerbrand's disease (author's transl)].

Authors:  C Mazurier; A Parquet-Gernez; M Goudemand
Journal:  Pathol Biol (Paris)       Date:  1977-12

4.  The bleeding disorder in hepatomegalic forms of glycogen storage disease.

Authors:  I M Nilsson; P A Ockerman
Journal:  Acta Paediatr Scand       Date:  1970-03

5.  Is glycogen storage disease 1a associated with atherosclerosis?

Authors:  Froukje L Ubels; Jan Peter Rake; Joris P J Slaets; G Peter A Smit; Andries J Smit
Journal:  Eur J Pediatr       Date:  2002-07-02       Impact factor: 3.183

6.  Inhibition of phosphomannose isomerase by fructose 1-phosphate: an explanation for defective N-glycosylation in hereditary fructose intolerance.

Authors:  J Jaeken; M Pirard; M Adamowicz; E Pronicka; E van Schaftingen
Journal:  Pediatr Res       Date:  1996-11       Impact factor: 3.756

Review 7.  Glycogen storage disease in adults.

Authors:  G M Talente; R A Coleman; C Alter; L Baker; B I Brown; R A Cannon; Y T Chen; J F Crigler; P Ferreira; J C Haworth; G E Herman; R M Issenman; J P Keating; R Linde; T F Roe; B Senior; J I Wolfsdorf
Journal:  Ann Intern Med       Date:  1994-02-01       Impact factor: 25.391

8.  Hyperlipidemia and fatty acid composition in patients treated for type IA glycogen storage disease.

Authors:  H L Greene; L L Swift; H R Knapp
Journal:  J Pediatr       Date:  1991-09       Impact factor: 4.406

9.  Plasma antioxidants in pediatric patients with glycogen storage disease, diabetes mellitus, and hypercholesterolemia.

Authors:  Birgit Wittenstein; Marcus Klein; Barbara Finckh; Kurt Ullrich; Alfried Kohlschütter
Journal:  Free Radic Biol Med       Date:  2002-07-01       Impact factor: 7.376

10.  The complex multimeric composition of factor VIII/von Willebrand factor.

Authors:  Z M Ruggeri; T S Zimmerman
Journal:  Blood       Date:  1981-06       Impact factor: 22.113

View more
  7 in total

Review 1.  Dietary dilemmas in the management of glycogen storage disease type I.

Authors:  Kaustuv Bhattacharya
Journal:  J Inherit Metab Dis       Date:  2011-04-14       Impact factor: 4.982

2.  Hyperlipidemia in glycogen storage disease type III: effect of age and metabolic control.

Authors:  A V Bernier; C P Sentner; C E Correia; D W Theriaque; J J Shuster; G P A Smit; D A Weinstein
Journal:  J Inherit Metab Dis       Date:  2008-08-19       Impact factor: 4.982

3.  Vascular dysfunction in glycogen storage disease type I.

Authors:  Angelina V Bernier; Catherine E Correia; Michael J Haller; Douglas W Theriaque; Jonathan J Shuster; David A Weinstein
Journal:  J Pediatr       Date:  2008-12-21       Impact factor: 4.406

Review 4.  Glycogen storage diseases: new perspectives.

Authors:  Hasan Ozen
Journal:  World J Gastroenterol       Date:  2007-05-14       Impact factor: 5.742

5.  Fertility and pregnancy in women affected by glycogen storage disease type I, results of a multicenter Italian study.

Authors:  Annalisa Sechi; Laura Deroma; Annunziata Lapolla; Sabrina Paci; Daniela Melis; Alberto Burlina; Francesca Carubbi; Miriam Rigoldi; Maja Di Rocco
Journal:  J Inherit Metab Dis       Date:  2012-05-05       Impact factor: 4.982

Review 6.  Investigation and management of the hepatic glycogen storage diseases.

Authors:  Kaustuv Bhattacharya
Journal:  Transl Pediatr       Date:  2015-07

7.  Patients with glycogen storage diseases undergoing anesthesia: a case series.

Authors:  Carmelina Gurrieri; Juraj Sprung; Toby N Weingarten; Mary E Warner
Journal:  BMC Anesthesiol       Date:  2017-10-06       Impact factor: 2.217

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.